New and old Cancer Drugs boost revenue for the Big Pharma. Total sales across the group were up 6% at constant exchange rates,
with its pharma division up 5% as sales reached CHF18.35bn ($19.21bn) in
the first six months of 2015.
Revenue was unsurprisingly buoyed
by its oncology drug range, with blood cancer and arthritis treatment
MabThera (rituximab) remaining its top-selling product, bringing in
sales of CHF3.5bn, a growth of 6% on last year.
Its ageing breast cancer drug Herceptin (trastuzumab) and multi-cancer licensed Avastin (bevacizumab) were both a close second, recording identical sales of CHF3.26bn, up 11% and 9% respectively.
No comments:
Post a Comment